Back

Multicenter study on the effect of Mavacamten on pulmonary artery systolic pressure derived from echo-doppler in obstructive hypertrophic cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Left ventricular outflow tract obstruction Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Maka Gegenava

Tbilisi State Medical University (TSMU), Tbilisi (Georgia)

6 More presentations in this session

Presentation thumbnail
Comparison of characteristics and outcomes of patients with obstructive vs. non-obstructive hypertrophic cardiomyopathy in a cohort from a referral center in colombia
Doctor J. Orozco Burbano (Medellin, CO)
Abstract Slides Video
Presentation thumbnail
Outcomes of alcohol septal ablation for obstructive hypertrophic cardiomyopathy in Japan
Doctor T. Yamaguchi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Genetic, echocardiographic and clinical determinants of mitral valve abnormalities in hypertrophic cardiomyopathy
Miss H. Panholzer (Graz, AT)
Abstract Slides Video
Presentation thumbnail
Common pathophysiological mechanism of SAM and mitral regurgitation in HOCM
Associate Professor Z. Wang (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure (polypharmacy phenogroups and heart failure subgroups outcomes)
Doctor A. Aboughalia (Doha, QA)
Abstract Slides Video

Access the full session

Session thumbnail
Left ventricular outflow tract obstruction

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Assessment of changes in right-sided cardiac echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment
thumbnail
Congress Presentation
Temporal changes in echocardiographic parameters of diastolic dysfunction in obstructive hypertrophic cardiomyopathy during mavacamten treatment
thumbnail
Congress Presentation
Reduction of >100 mmHg left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy during mavacamten treatment already after one week of treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources